| Name | Title | Contact Details |
|---|
CuraPharm Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology and infectious diseases. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology and infectious diseases, including COVID-19. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, Berlin and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.
HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
Ÿnsect is the world leader in the production of protein and natural insect fertilizers. Founded in 2011 in Paris, France, by both scientists and environmental activists, Next40 and B Corp-certified, the company processes insects into high-end, high-value ingredients for pets, fish, plants and humans. From its purpose-built state-of-the-art farms, Ÿnsect offers a long-term, sustainable, organic solution to accelerate protein and plant consumption. Ÿnsect uses pioneering proprietary technology covered by 377 patents across 44 categories, to produce lesser and yellow mealworms in fully automated vertical farms. Ÿnsect runs three production sites, one in Dole, France (commissioned 2016), one in the Netherlands (2017), one in the USA (since 2022), and a third site, the world`s largest vertical farm, in Amiens in France, is currently under construction. The company, which employs 360+ people, has raised around $ 500 million from major global investment funds, banks and public bodies and exports its products around the world.